| Jason Hamlin is the founder of Nicoya Research and has published investment research for over a decade. He previously worked in data analytics for Nielsen, the world’s largest market research firm, where he consulted to Fortune 500 companies including Nestlé, Johnson & Johnson and Del Monte. Jason eventually left the corporate world and leveraged his analytical skills to successfully trade stocks full-time while traveling the world. After helping his parents 5x their investment portfolio in under two years, Jason decided to start Nicoya Research and share his investment research and strategies to help other people find success and financial freedom. | 
For some, “psychedelic” and “medicine” are synonymous, and together, powerful. Investment into psychedelic drug companies is accelerating accordingly. Even before the 2020 election, when Oregon decriminalized all drugs including psychedelic substances and Washington D.C. decriminalized psilocybin mushrooms and entheogenic plants, the phrase “psychedelics industry” was increasingly being uttered by investors, researchers, and entrepreneurs alike. The […]
